Freenome Reports Third Quarter 2026 Financial Results

Freenome reported total revenue of $183.5 million for the third quarter of 2026, a significant increase compared to $1.0 million in the same period of 2025. The revenue was primarily driven by $180.0 million recognized under a collaboration and license agreement following the FDA approval of the company's SimpleScreen CRC test. The company ended the quarter with $430.0 million in cash, cash equivalents, and marketable securities. Freenome also provided full-year 2026 revenue guidance of $192 million to $194 million, which includes contributions from license and collaboration agreements, research and development services, and early commercial activities.